Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancers
This study provides novel insights into the role of TMPRSS2 in various tumor systems and the impact of SARS-CoV-2 infection on the host immunogenicity via the activation of immune-relevant pathways. These findings were linked to the efficacy of immune checkpoint inhibitor therapy, offering a potential alternative strategy to mitigate the severity of COVID-19.
Authors
- S M Al Amin Hossain
- Karthikeyan Subbarayan (ORCID: https://orcid.org/0000-0002-5140-0253)
- Barbara Seliger (ORCID: https://orcid.org/0000-0002-5544-4958)
- Wafa Wahbi (ORCID: https://orcid.org/0000-0001-9416-5196)
- Tuula Anneli Salo (ORCID: https://orcid.org/0000-0001-6039-0088)
- Ahmed Al‐Samadi (ORCID: https://orcid.org/0000-0003-1938-2136)
- Sandy Tretbar (ORCID: https://orcid.org/0000-0003-3616-8414)
- Francisco Rodríguez
- Chiara Massa
- Helena Bieber
- Lisa Neuder
Institutions
- University of Helsinki (FI)
- University of Eastern Finland (FI)
- Center of Molecular Immunology (Cuba) (CU)
- University of Havana (CU)
- University of Information Science (CU)
- Fraunhofer Institute for Cell Therapy and Immunology (DE)
- Medizinische Hochschule Brandenburg Theodor Fontane (DE)
- Universitätsklinikum Brandenburg an der Havel (DE)
- Martin Luther University Halle-Wittenberg (DE)
- University of Oulu (FI)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1186/s12967-025-06177-z
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00